Richard R. Furman

NewYork–Presbyterian Hospital — United States

Medicine · Health Sciences

75h-index32.8kcitations494works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(347), Lymphoma Diagnosis and Treatment(275), Immunodeficiency and Autoimmune Disorders(65), Chronic Myeloid Leukemia Treatments(57), Monoclonal and Polyclonal Antibodies Research(54)

Publications493 total

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies
Blood·2025
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.
Blood·2025Open Access
Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).
Blood·2025Open Access
Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).
Blood·2025Open Access
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi
Cell Genomics·2025Open Access
Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples
Clinical Epigenetics·2025· 2 citedOpen Access
Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy
Transplantation and Cellular Therapy·2025Open Access
Complementary approaches define the metabolic features that accompany Richter syndrome transformation
Cellular and Molecular Life Sciences·2025· 1 citedOpen Access
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry
Blood Cancer Journal·2025· 2 citedOpen Access
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia
Hematological Oncology·2024· 3 citedOpen Access
Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience
Blood·2024Open Access
Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience
Blood·2024
Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTKC481S-Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia
Blood·2024· 1 citedOpen Access
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib
Blood Advances·2024· 15 citedOpen Access
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Blood Advances·2024· 6 citedOpen Access
Supplementary Table 1 from XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells
2024Open Access
Data from XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells
2024Open Access
Data from XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells
2024Open Access
Supplementary Data from XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells
2024Open Access
Supplementary Table 1 from XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells
2024Open Access
page 1 of 25Next →

Frequent Co-authors

Steven Coutré(16), John C. Byrd(14), Morton Coleman(13), Susan O’Brien(13), Jennifer R. Brown(12), John P. Leonard(12), Peter Hillmen(11), Danelle F. James(10), Jeff P. Sharman(9), William G. Wierda(9), Jeffrey A. Jones(9), Jacqueline C. Barrientos(9), Ian W. Flinn(8), Amy J. Johnson(8), John M. Pagel(8), Jennifer A. Woyach(8), Kristie A. Blum(7), Thomas J. Kipps(7), Stephan Stilgenbauer(7), Paul M. Barr(7)